Omicron News and Research

RSS

Early treatment of COVID-19 in high-risk children and adolescents infected with the Omicron variant of SARS-CoV-2

Researchers discussed patient features, treatment-associated process measures, and outcomes associated with early monoclonal antibody and antiviral therapy in high-risk pediatric patients infected with the SARS-CoV-2 Omicron variant.

22 Mar 2022

Length of stay distributions of hospitalized COVID-19 cases during a mixed Omicron-Delta epidemic in Australia

Researchers determined the hospital stay lengths for COVID-19 patients infected by the Omicron and Delta variants of SARS-CoV-2.

22 Mar 2022

Posaconazole found to be effective as a small molecule fusion inhibitor against SARS-CoV-2 variants

Researchers evaluated the importance of the Ex3Lx6L motif in SARS-CoV-2 entry into host cells mediated by the spike protein syncytium formation and membrane fusion.

22 Mar 2022

Research characterizes efficacy of various COVID vaccines against Omicron BA.1 and BA.2

A recent study posted to the bioRxiv* preprint server demonstrated the neutralizing capacity of existing SARS-CoV-2 vaccines against the severe acute respiratory coronavirus 2 (SARS-CoV-2) Omicron BA.2 and BA.1 sublineages.

22 Mar 2022

SARS-CoV-2 infection risk among dialysis patients during Omicron surge

A recent study posted to the medRxiv* preprint server evaluated the antibody responses against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) patients receiving hemodialysis.

22 Mar 2022

Is COVID-19 on the verge of ending?

Researchers explore the changes arising in SARS-CoV-2 over time.

21 Mar 2022

A circRNA COVID vaccine with potential to neutralize SARS-CoV-2 variants

Researchers demonstrate the broad neutralization potential of a strategically engineered circRNA using mice as a model system.

21 Mar 2022

Oral drug that reverses immune aging effectively prevents death in COVID-19 mouse model

The immune system deteriorates with age, making COVID-19 particularly deadly in older people -; but to date, no clinically available medication addresses this key risk factor.

21 Mar 2022

Clinical severity of SARS-CoV-2-Omicron infection found to be lower than Delta infection

Researchers evaluated the severity of SARS-CoV-2cc infection by the Omicron variant compared to the Delta variant.

21 Mar 2022

Phase 2 trial evaluates the safety and immunogenicity of two doses of the SARS-CoV-2 vaccine MVC-COV1901 in adolescents

A recent study evaluated the safety and immunogenicity of a COVID-19 vaccine in a phase II trial.

21 Mar 2022

Study aimed to identify the direct pathway that associates integrins with vascular dysregulation during SARS-CoV-2 infection

Researchers demonstrated the role of integrin signaling in vascular dysfunction associated with SARS-CoV-2 infection.

21 Mar 2022

Neutralizing antibody responses against parental SARS-CoV-2 strain as well as against Omicron BA.1 and BA.2 variants

Researchers evaluated the immune responses in individuals vaccinated with the BNT162b2 vaccine.

21 Mar 2022

Pfizer CEO pushes yearly shots for covid. Not so fast, experts say.

When Pfizer CEO Albert Bourla said March 13 that all Americans would need a second booster shot, it struck many covid experts as a self-serving remark without scientific merit. It also set off spasms of doubt over the country's objectives in its fight against the coronavirus.

21 Mar 2022

Omicron News and Research

Early treatment of COVID-19 in high-risk children and adolescents infected with the Omicron variant of SARS-CoV-2

Length of stay distributions of hospitalized COVID-19 cases during a mixed Omicron-Delta epidemic in Australia

Posaconazole found to be effective as a small molecule fusion inhibitor against SARS-CoV-2 variants

Research characterizes efficacy of various COVID vaccines against Omicron BA.1 and BA.2

SARS-CoV-2 infection risk among dialysis patients during Omicron surge

Is COVID-19 on the verge of ending?

A circRNA COVID vaccine with potential to neutralize SARS-CoV-2 variants

Oral drug that reverses immune aging effectively prevents death in COVID-19 mouse model

Clinical severity of SARS-CoV-2-Omicron infection found to be lower than Delta infection

Phase 2 trial evaluates the safety and immunogenicity of two doses of the SARS-CoV-2 vaccine MVC-COV1901 in adolescents

Study aimed to identify the direct pathway that associates integrins with vascular dysregulation during SARS-CoV-2 infection

Neutralizing antibody responses against parental SARS-CoV-2 strain as well as against Omicron BA.1 and BA.2 variants

Pfizer CEO pushes yearly shots for covid. Not so fast, experts say.

The importance of the endosomal pathway for SARS-CoV-2 entry

Multiple inter-variant recombination events identified in Omicron subvariants

Sinovac COVID vaccine shows modest efficacy against SARS-CoV-2 infection in children 3 to 5 years

Omicron BA.1.1 and BA.2 subvariants with new mutations in New Zealand and Hong Kong

Natural circulating antibodies last for at least seven months in children infected with COVID-19

Texas Biomed and UAB partnership uncovers a new, potent antibody cocktail against all coronaviruses

Study evaluates COVID-19 vaccination with recombinant accessory protein-deficient SARS-CoV-2

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News